Equillium, Inc.
$2.01
▼
-3.43%
2026-04-21 06:40:01
www.equilliumbio.com
NCM: EQ
Explore Equillium, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$127.09 M
Current Price
$2.01
52W High / Low
$2.7 / $0.27
Stock P/E
—
Book Value
$0.47
Dividend Yield
—
ROCE
-81.63%
ROE
-94%
Face Value
—
EPS
$-0.39
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
1.74
Debt / Equity
2.51
Current Ratio
10.58
Quick Ratio
10.58
Forward P/E
-6.86
Price / Sales
—
Enterprise Value
$84.25 M
EV / EBITDA
-3.58
EV / Revenue
—
Rating
Strong Buy
Target Price
$6.4
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Entrada Therapeutics, Inc. | $13.56 | — | $535.6 M | — | -44.74% | -39.13% | $14.49 / $4.93 | $8.5 |
| 2. | Lite Strategy, Inc. | $1.19 | — | $42.54 M | 0% | -103.09% | -76.38% | $9 / $0.95 | $2.23 |
| 3. | BioMarin Pharmaceutical Inc. | $54.33 | 30.1 | $10.47 B | — | 5.99% | 5.94% | $66.28 / $50.76 | $31.65 |
| 4. | AgomAb Therapeutics NV | $10.79 | — | $0.28 M | — | -24.35% | -27.25% | $17.45 / $9 | $-7,123.4 |
| 5. | Alumis Inc. | $24.71 | — | $3.18 B | — | -134.01% | -86.68% | $30.6 / $2.76 | $2.88 |
| 6. | Corbus Pharmaceuticals Holdings, Inc. | $10.62 | — | $188.36 M | — | -57.84% | -54.18% | $20.56 / $5.75 | $8.38 |
| 7. | TuHURA Biosciences, Inc. | $2.83 | — | $179.93 M | 0% | -120.19% | -1.69% | $4.44 / $0.41 | $0.35 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 4.39 M | — |
| Operating Profit | -3.96 M | -4.58 M | -6.23 M | -8.87 M | -4.7 M | — |
| Net Profit | -3.77 M | -4.23 M | -5.74 M | -8.65 M | -5.79 M | — |
| EPS in Rs | -0.06 | -0.07 | -0.09 | -0.14 | -0.09 | 0 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 41.09 M | 36.08 M | 15.76 M |
| Operating Profit | -23.63 M | -8.27 M | -14.52 M | -39.03 M |
| Net Profit | -22.4 M | -8.07 M | -13.34 M | -62.43 M |
| EPS in Rs | -0.35 | -0.13 | -0.21 | -0.99 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 31.89 M | 25.6 M | 50.53 M | 78.42 M |
| Total Liabilities | 3.29 M | 6.54 M | 27.96 M | 46.48 M |
| Equity | 28.6 M | 19.06 M | 22.57 M | 31.94 M |
| Current Assets | 31.04 M | 24.98 M | 49.35 M | 76.73 M |
| Current Liabilities | 2.93 M | 6.36 M | 27.57 M | 32.04 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -22.75 M | -19.03 M | -21.78 M | -8.73 M |
| Investing CF | 4.46 M | 13.81 M | -4.76 M | 18.68 M |
| Financing CF | 30.43 M | 0.16 M | -9.23 M | -1.22 M |
| Free CF | -22.79 M | -19.11 M | -21.83 M | -9.01 M |
| Capex | -0.05 M | -0.09 M | -0.05 M | -0.28 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 13.89% | 128.97% | — | — |
| Earnings Growth % | 39.51% | 78.64% | — | — |
| Profit Margin % | -19.63% | -36.96% | -396.14% | — |
| Operating Margin % | -20.12% | -40.24% | -247.65% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -19.79% | -33.64% | -388.71% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.